Clinical Trial Detail

NCT ID NCT03315871
Title Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

prostate cancer

Therapies

CV301 + M7824 + PROSTVAC-F/TRICOM + PROSTVAC-V/TRICOM

Age Groups: adult senior

No variant requirements are available.